Abstract
Meningiomas are considered the second most common neoplasm of the central nervous system in adults. Most of them are benign with slow growth, frequent in women and with a high recurrence rate. In tumors, DNA error repair processes lose efficacy, providing mutagenesis and genomic instability. This work evaluated the expression of proteins involved in cell synthesis (cyclin D1) and DNA errors repair (MUTYH, XPF, XPG) in meningiomas, relating them to clinical, tumor and survival variables. The study included 85 patients, with a mean age of 52 ± 13.3 years and most of them women (2:1 ratio). Sixty-seven cases were grade I (79%). Grade II tumors were independent predictors of recurrence-regrowth (HR: 2.8; p = 0.038). The high expression of cyclin D1 was associated with grade II (p = 0.001) and low MUTYH expression with grade I (p = 0.04). Strong expression of XPF and XPG was associated with grade II (p = 0.002; p < 0.001) and with recurrence-regrowth (p = 0.04; p = 0.003). Strong XPF expression was significantly related to large tumors (p = 0.03). An association of cyclin D1, MUTYH and XPF were found. Survival was not associated with the expression of any of the proteins studied. To know the role of DNA repair proteins and cell synthesis is important for understanding the processes of origin and tumor development. Grade II meningiomas and strong expression of XPF and XPG were predictors of recurrence or regrowth and may assist in clinical management, considering the high recurrence of meningiomas and the absence of consensus regarding treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbritti RV, Polito F, Cucinotta M et al (2016) Meningiomas and proteomics: focus on new potential biomarkers and molecular pathways. Cancer Genomics Proteomics 13:369–379
Almeida AN, Pereira BJA, Pires Aguiar PH et al (2017) Clinical outcome, tumor recurrence, and causes of death: a long-term follow-up of surgically treated meningiomas. World Neurosurg 102:139–143. https://doi.org/10.1016/j.wneu.2017.03.009
Aracil M, Dauffenbach LM, Diez MM et al (2013) Expression of XPG protein in human normal and tumor tissues. Int J Clin Exp Pathol 6:199–211
Azar M, Kazemi F, Jahanbakhshi A et al (2017) Gamma knife radiosurgery for cavernous sinus meningiomas: analysis of outcome in 166 patients. StereotactFunctNeurosurg 95:259–267. https://doi.org/10.1159/000478024
Banda DM, Nunez NN, Burnside MA, Bradshaw KM, David SS (2017) Repair of 8-oxoG: a mismatches by the MUTYH glycosylase: mechanism, metals and medicine. Free Radic Biol Med 107:202–215
Bertero L, Dalla Dea G, Osella-Abate S et al (2019) Prognostic characterization of higher-grade meningiomas: a histopathological score to predict progression and outcome. J Neuropathol Exp Neurol 78:248–256 PMID: 30689922
Black JO (2016) Xeroderma Pigmentosum. Head Neck Pathol 10:139–144. https://doi.org/10.1007/s12105-016-0707-8
Bumrungrachpukdee P, Pruphetkaew N, Phukaoloun M, Pheunpathom N (2014) Recurrence of intracranial meningioma after surgery: analysis of influencing factors and outcome. J Med Assoc Thai 97:399–406
Chen SY, Chen HH, Huang YC et al (2017) Polymorphism and protein expression of MUTYH gene for risk of rheumatoid arthritis. BMC MusculoskeletDisord 7:69. https://doi.org/10.1186/s12891-017-1437-0
Cheng G, Zhang L, Lv W, Dong C, Wang Y, Zhang J (2015) Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression. Med Oncol 32:439. https://doi.org/10.1007/s12032-014-0439-0
Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, Van Belle G (2006) Hormonal exposures and the risk of intracranial meningioma in women: a population based case-control study. BMC Cancer 6:152–155. https://doi.org/10.1186/1471-2407-6-152
Deloia JA, Bhagwat NR, Darcy KM et al (2012) Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol Oncol 126(3):448–454 PMID: 22609620
Deng N, Liu JW, Sun L et al (2014) Expression of XPG protein in the development, progression and prognosis of gastric cancer. PLoS ONE 9:e108704. https://doi.org/10.1371/journal.pone.0108704
Di Franco R, Borzillo V, Ravo V et al (2017) Radiosurgery and stereotactic radiotherapy with cyber knife system for meningioma treatment. Neuroradiol J 31:18–26. https://doi.org/10.1177/1971400917744885
El-Gewely MR, Andreassen M, Walquist M et al (2016) Differentially expressed microRNAs in meningiomas grades I and II suggest shared biomarkers with malignant tumors. Cancers (Basel.) 8:S31. https://doi.org/10.3390/cancers8030031
Friedberg EC (2015) A history of the DNA repair and mutagenesis field: I. The discovery of enzymatic photoreactivation. DNA Repair (Amst) 33:35–42. https://doi.org/10.1016/j.dnarep.2015.06.007
Gallagher MJ, Jenkinson MD, Brodbelt AR, Mills SJ, Chavredakis E (2016) WHO grade 1 meningioma recurrence: Are location and Simpson grade still relevant? Clin Neuro Neurosurg 141:117–121. https://doi.org/10.1016/j.clineuro.2016.01.006
Gao D, Wei C, Chen L, Huang J, Yang S, Diehl AM (2004) Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am J PhysiolGastrointest Liver Physiol 287:G1070–G1077. https://doi.org/10.1152/ajpgi.0010.1152/ajpgi.00228.2004
Garzon-Muvdi T, Yang W, Lim M, Brem H, Huang J (2017) Atypical and anaplastic meningioma: outcomes in a population based study. J Neurooncol 133:321–330. https://doi.org/10.1007/s11060-017-2436-6
Harter PN, Braun Y, Plate KH (2017) Classification of meningioma advances and controversies. Chin Oncol 6:S2. https://doi.org/10.21037/cco.2017.05.02
Hatch SB, Swift LP, Caporali S et al (2014) XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection. Int J Cancer 134:1495–1503. https://doi.org/10.1002/ijc.28454
He Q, Wu J, Liu XL et al (2017) Clinicopathological and prognostic significance of cyclin D1 amplification in patients with breast cancer: a meta-analysis. J Buon 22:1209–1216
Huagn J, Liu X, Ling-Ling T et al (2017) XPG sgene polymorphisms and cancer susceptibility: evidence from 47 studies. Oncotarget 8:37263–37277. https://doi.org/10.18632/oncotarget.16146
Jimeno S, Herrera-Moyano E, Ortega P, Aguilera A (2017) Differential effect of the overexpression of Rad2/XPG family endonucleases on genome integrity in yeast and human cells. DNA Repair (Amst) 57:66–75. https://doi.org/10.1016/j.dnarep.2017.06.030
Jiricny J (2000) Mediating mismatch repair. Nat Genet 24:6–8
Kalani MY, Cavallo C, Coons SW et al (2015) Long-term follow-up of surgical resection of microcystic meningiomas. J Clin Neurosci 22:713–717. https://doi.org/10.1016/j.jocn.2014.12.004
Kanter M, Turan G, Usta C et al (2016) Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms. J Mol Histol 47:145–152
Karimi S, Vyas MV, Gonen L et al (2017) Prognostic significance of preoperative neutrofilia on recurrence free survival in meningioma. Neuro Oncol 19:1503–1510. https://doi.org/10.1093/neuonc/nox089
Karsy M, Guan J, Cohen A et al (2016) Medical management of meningiomas: current status, failed treatment and promising horizons. Neurosurg Clin N Am 27:249–260. https://doi.org/10.1016/j.nec.2015.11.002
Kim MS, Kim HM, Lee EH et al (2014) Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas. J Neurosurg 121(5):1189–1200 PMID: 25148008
Kim H, Park KJ, Ryu BK et al (2020) Forkhead Box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression. Neuropathol Appl Neurobiol 46(2):125–141
Koch SC, Simon N, Ebert C, Carrel T (2016) Molecular mechanisms of xeroderma pigmentosum (XP) proteins. Q Ver Biophys 49:e5
Koelsche C, Sahm F, Capper D et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907–915
Koyama Y, Higashimoto M, Gonda K et al (2010) Expression of Xeroderma Pigmentosum Group G (XPG) in sporadic breast carcinoma. Ann Cancer Res Therap 18:37–42. https://doi.org/10.4993/acrt.18.37
Krawczyk MA, Karpinsky G, Izycka-Swieszewska E et al (2019) Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerves heath tumor. Cancer Biomark 24:351–361. https://doi.org/10.3233/CBM-181572
Louis DN, Perry A, Reifenberger G (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
Luo KQ, Mu SQ, Wu ZX et al (2013) Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev 14:449–452. https://doi.org/10.7314/apjcp.2013.14.1.449
Magill ST, Young JS, Chae R, Aghi MK, Theodosopoulos PV, McDermott MW (2018) Relationship between tumor location, size, and WHO grade in meningioma. Neurosurg Focus 44:E4. https://doi.org/10.3171/2018.1.FOCUS17752
Mc Neil KA (2016) Epidemiology of brain tumors. Neurol Clin 34:981–998. https://doi.org/10.1016/j.ncl.2016.06.014
Milenković S, Marinkovic T, Jovanovic MB, Djuricic S, Berisavac II, Berisavac I (2008) Cyclin D1 immunoreactivity in meningiomas. Cell Mol Neurobiol 28:907–913. https://doi.org/10.1007/s10571-008-9278-x
Mirian C, Duun-Henriksen AK, Juratli T (2020) Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. J Neurol Neurosurg Psychiatry 91:378–387
Moon HS, Jung S, Jang WY, Jung TY, Moon KS, Kim IY (2012) Intracranial meningiomas, WHO Grade II: prognostic implications of clinic pathologic features. J Korean Neurosurg Soc 52:14–20
Nassiri F, Mamatjan Y, Suppiah S et al (2019) DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology 21(7):901–910 (PMID:31158293)
Norden AD, Ligon KL, Hammond SN et al (2015) Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 84:280–286. https://doi.org/10.1212/WNL.0000000000001153
Nowak A, Dziedzic T, Krych P, Czernicki T, Kunert P, Marchel A (2015) Benign versus atypical meningiomas: risk factors predicting recurrence. Neurol Neurochir Pol 49:1–10. https://doi.org/10.1016/j.pjnns.2014.11.003
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 20:1–86. https://doi.org/10.1093/neuonc/noy131
Oya S, Kim S-H, Sade B et al (2011) The natural history of intracranial meningiomas. J Neurosurg 114:1250–1256. https://doi.org/10.3171/2010.12.JNS101623
Perry A (2018) Meningiomas. In: Perry A, Brat DJ (eds) Practical surgical neuropathology a diagnostic approach. Churchill Living stone Elsevier, Philadelphia, pp 259–296
Proctor DT, Ramachandran S, Lama S, Sutherland GR (2018) Towards molecular classification of meningioma: evolving treatment and diagnostic paradigms. World Neurosurg 119:366–373. https://doi.org/10.1016/j.wneu.2018.08.019
Rajaraman P, Hutchinson A, Wichner S et al (2010) DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol 12:37–48. https://doi.org/10.1093/neuonc/nop012
Ramos-García P, González-Moles MÁ, Ayén Á, González-Ruiz L, Gil-Montoya JA, Ruiz-Ávila I (2019) Predictive value of CCND1/cyclin D1 alterations in the malignant transformation of potentially malignant head and neck disorders: systematic review and meta-analysis. Head Neck 41:3395–3407
Ravikumar G, Ananthamurthy A (2014) Cyclin D1 expression in ductal carcinoma of the breastand its correlation with other prognostic parameters. J Cancer Res Ther 10:671–675. https://doi.org/10.4103/0973-1482.138135
Romani R, Ryan G, Benner C, Pollock J (2018) Non-operative meningiomas: long-term follow-up of 136 patients. Acta Neurochir (Wien) 160:1547–1553. https://doi.org/10.1007/s00701-018-3554-4
Rose PG, Java J, Whitney CW et al (2015) Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from oncology/gynecologic oncology group randomized trials of chemoradiotherapy. J Clin Oncol 33:2136–2142. https://doi.org/10.1200/JCO.2014.57.7122
Sahm F, Schrimpf D, Olar A et al (2017) TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst 108:djv377
Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39. https://doi.org/10.1136/jnnp.20.1.22
Splavski B, Hadzic E, Bagic I et al (2017) Simple tumor localization scale for estimating management outcome of intracranial meningioma. World Neurosurg 104:876–882. https://doi.org/10.1016/j.wneu.2017.05.039
Staresincic L, Fagbemi AF, Enzlin JH et al (2009) Coordination of dual incision and repair synthesis in human nucleotide excision repair. EMBO J 28:1111–1120. https://doi.org/10.1038/emboj.2009.49
Su Y, Zhang H, Xu F, Kong J, Yu H, Qian B (2015) DNA repair gene polymorphisms in relation to non-small cell lung cancer survival. Cell PhysiolBiochem 36:1419–1429
Sulman EP, White PS, Brodeur GM (2004) Genomic an notation of the meningioma tumor supressor locus on chromosome 1p34. Oncogene 23:1014–1020. https://doi.org/10.1038/sj.onc.1206623
Tao X, DongJ HouZ et al (2018) Clinical features, treatment, and prognostic factors of 56 intracranial and intraspinal clear cell meningiomas. World Neurosurg 111:880–887. https://doi.org/10.1016/j.wneu.2017.12.173
Voß KM, Spille DC, Sauerland C et al (2017) The Simpson grading in meningioma surgery: does the tumor location influence the prognostic value? J Neurooncol 133:641–651. https://doi.org/10.1007/s11060-017-2481-1
Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neurooncol 99:307–314. https://doi.org/10.1007/s11060-010-0386-3
Wu H, Li S, Hu X et al (2019) Associations of mRNA expression of DNA repair genes and genetic polymorphisms with cancer risk: a bioinformatics analysis and meta-analysis. J Cancer 10:3593–3607. https://doi.org/10.7150/jca.30975
Zada G, Başkaya MK, Shah MV (2017) Introduction: surgical management of skull base meningiomas. Neurosurg Focus. https://doi.org/10.3171/2017.10.FocusVid.Intro
Zouaoui S, Darlix A, Rigau V et al (2018) Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie 64:15–21. https://doi.org/10.1016/j.neuchi.2014.11.013
Acknowledgements
This work was supported by grants from CAPES (Brazilian government research funding agency).
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Silva CBO, Ongaratti B, Trott Geraldine and Araújo B. The first draft of the manuscript was written by Pereira-Lima JFS and Oliveira MC and all authors commented on previous versions of the manuscript. Ferreira NP and Rech CSL also contributed in analysis of medical records and Barbosa Coutinho L was the pathologist responsible for the histopathological diagnosis of all the cases. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
de Oliveira Silva, C.B., Ongaratti, B.R., Trott, G. et al. DNA repair and cell synthesis proteins: immunohistochemical expression and correlation with recurrence-regrowth in meningiomas. J Mol Hist 51, 411–420 (2020). https://doi.org/10.1007/s10735-020-09892-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-020-09892-7